A Phase II Trial of NeuVax Adjuvant Treatment in Node Positive and Node Negative, HER2 1+, 2+ and 3+ Breast Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 30 May 2014
At a glance
- Drugs Nelipepimut-S (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors RXi Pharmaceuticals
- 30 May 2014 New trial record
- 06 Jun 2011 According to a RXi Pharmaceuticals media release, data presented at the American Society of Clinical Oncology (ASCO).
- 06 Jun 2011 The primary endpoint 'Disease-free-survival' has been met according to the Galena Biophram media release.